Fortunato Ciardiello

Fortunato Ciardiello's AcademicInfluence.com Rankings

Philosophy

#3718

World Rank

#5954

Historical Rank

Logic

#1353

World Rank

#2084

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Fortunato Ciardiello's Degrees

PhD Biomedical Sciences University of Naples Federico II
Doctorate Medicine University of Naples Federico II

Why Is Fortunato Ciardiello Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fortunato Ciardiello's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2017) (3388)
Epidermal growth factor-related peptides and their receptors in human malignancies. (1995) (2800)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
EGFR antagonists in cancer treatment. (2008) (1911)
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (2011) (1721)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) (1300)
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001) (1008)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (2000) (989)
Chronic inflammation and oxidative stress in human carcinogenesis (2007) (858)
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. (2001) (654)
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (646)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (2019) (620)
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) (611)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) (577)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. (2012) (540)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. (2011) (533)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017) (532)
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. (2002) (459)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (2009) (403)
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (395)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS (2018) (370)
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy (2004) (343)
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. (1999) (339)
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. (2003) (330)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. (2007) (325)
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. (2015) (322)
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. (1998) (319)
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. (1997) (306)
Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy (2009) (304)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) (298)
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. (2002) (294)
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer (2005) (288)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. (2019) (282)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. (2008) (268)
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). (2002) (265)
Differential expression of epidermal growth factor-related proteins in human colorectal tumors. (1991) (261)
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. (2005) (255)
Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib (2007) (250)
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. (2003) (238)
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012) (233)
Treatment of gastric cancer. (2014) (232)
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. (2007) (226)
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (216)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials (2005) (200)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study (2015) (199)
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. (2019) (190)
ALK inhibitors in the treatment of advanced NSCLC. (2014) (170)
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients (2005) (163)
Global cancer control: responding to the growing burden, rising costs and inequalities in access (2018) (159)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study (2019) (157)
Key cancer cell signal transduction pathways as therapeutic targets. (2006) (156)
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. (2011) (151)
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. (1996) (150)
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. (2003) (149)
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. (2013) (146)
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells (2008) (141)
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer (2007) (140)
Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. (1992) (138)
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. (2000) (136)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs (2008) (136)
Rational bases for the development of EGFR inhibitors for cancer treatment. (2007) (133)
Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells (1990) (129)
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. (2005) (129)
Targeting EGFR in pancreatic cancer treatment. (2012) (128)
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. (2015) (125)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study (2021) (124)
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells (2013) (123)
Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas (2004) (123)
Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. (1994) (122)
Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery (2006) (121)
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. (2012) (121)
Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. (1990) (118)
Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge (2018) (118)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. (2021) (118)
Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data (2007) (118)
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology (2020) (118)
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. (2006) (117)
Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. (2014) (117)
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications (2008) (115)
Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. (1991) (113)
Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues (1996) (110)
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. (2010) (110)
Transforming growth factor-alpha: an oncodevelopmental growth factor. (1990) (109)
The role of EGFR inhibitors in nonsmall cell lung cancer (2004) (109)
Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells. (1994) (109)
EGFR-targeted therapy. (2011) (108)
Erlotinib in non-small cell lung cancer treatment: current status and future development. (2007) (107)
Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines (2013) (107)
PARP inhibitors in ovarian cancer. (2019) (106)
The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor (1997) (105)
Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells* (1997) (105)
Pulmonary Large-Cell Neuroendocrine Carcinoma (2015) (104)
Anti-epidermal growth factor receptor drugs in cancer therapy (2002) (104)
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
Erlotinib in cancer treatment. (2007) (102)
Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy (2002) (99)
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. (2006) (97)
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer (2015) (96)
Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. (1994) (95)
ZD1839 (IRESSA), an EGFR‐selective tyrosine kinase inhibitor, enhances taxane activity in bcl‐2 overexpressing, multidrug‐resistant MCF‐7 ADR human breast cancer cells (2002) (94)
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. (2018) (94)
Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management (2015) (94)
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). (2007) (94)
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. (2016) (93)
Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. (2017) (93)
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. (2007) (93)
Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. (1998) (93)
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells (2013) (93)
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. (2005) (92)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. (2014) (92)
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines (2001) (89)
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. (2010) (89)
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets (2017) (88)
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC (2016) (88)
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC (2013) (87)
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. (2016) (87)
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition (2014) (87)
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. (2010) (86)
Transforming growth factor-alpha messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. (1990) (86)
Invasive phenotype of MCF10A cells overexpressing c‐Ha‐ras and c‐erbB‐2 oncogenes (1995) (85)
Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma (2005) (84)
Angiogenesis: a target for cancer therapy. (2004) (83)
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial (2018) (83)
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. (2020) (82)
Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma (2016) (81)
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer (2006) (81)
Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA (1989) (80)
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence (2016) (79)
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. (1998) (78)
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells (2010) (77)
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. (2007) (77)
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors (2006) (77)
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. (2010) (76)
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. (2003) (76)
Infection with a TGF-alpha retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts. (1989) (76)
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer (2005) (75)
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. (2007) (75)
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper (2014) (75)
Regulation by Estrogen through the 5′-Flanking Region of the Transforming Growth Factor α Gene (1991) (75)
Guideline on the requirements of external quality assessment programs in molecular pathology (2012) (74)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (2018) (74)
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy (2018) (73)
Additive effects of c‐erbB‐2, c‐Ha‐ras, and transforming growth factor‐α genes on in vitro transformation of human mammary epithelial cells (1992) (73)
Second-Line Treatment of Advanced Non-small Cell Lung Cancer (2008) (73)
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. (2016) (72)
Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts (2000) (71)
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. (2016) (70)
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. (1990) (70)
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. (2000) (70)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. (2019) (70)
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs (2018) (69)
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. (1999) (68)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial (2020) (68)
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. (2008) (68)
Epidermal growth factor receptor inhibitors in cancer treatment. (2005) (67)
A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer (2000) (67)
Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas (1995) (66)
The RIalfa subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. (1994) (66)
NM23 gene expression correlates with cell growth rate and S‐phase (1995) (65)
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts (2007) (65)
The role of amphiregulin in breast cancer (2004) (64)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. (2015) (63)
Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. (1994) (63)
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer (2017) (63)
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer (2017) (63)
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab (2015) (63)
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. (2014) (62)
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. (2003) (62)
Role and targeting of anaplastic lymphoma kinase in cancer (2018) (62)
Epidermal growth factor-related peptides in the pathogenesis of human breast cancer (2004) (61)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents (2012) (61)
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
Site‐selective 8‐chloroadenosine 3′,5′‐cyclic monophosphate inhibits transformation and transforming growth factor α production in Ki‐ras‐transformed rat fibroblasts (1989) (60)
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients (2017) (60)
Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. (1996) (60)
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells (2015) (60)
Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases (2006) (60)
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer (2006) (58)
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). (2014) (58)
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota (2018) (58)
Stromal influences on transformation of human mammary epithelial cells overexpressing c‐myc and SV40T (1990) (58)
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis (2016) (58)
Antitumor Effects of ZD 6474 , a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor , with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase 1 (2003) (57)
Neo-adjuvant and adjuvant chemotherapy of gastric cancer. (2007) (56)
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. (2000) (56)
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. (2004) (56)
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. (2009) (56)
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. (2022) (55)
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. (1997) (54)
Resistance to taxanes is induced by c‐erbB‐2 overexpression in human MCF‐10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A (2000) (54)
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. (2011) (54)
Induction of transforming growth factor alpha expression in mouse mammary epithelial cells after transformation with a point-mutated c-Ha-ras protooncogene. (1988) (54)
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance (2013) (54)
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. (2010) (54)
Improving outcomes in colorectal cancer: where do we go from here? (2013) (53)
Patient‐Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small‐cell Lung Cancer (2018) (53)
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. (2003) (52)
Expression of transforming growth factor α antisense mRNA inhibits the estrogen‐induced production of TGFα and estrogen‐induced proliferation of estrogen‐responsive human breast cancer cells (1993) (52)
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (2011) (52)
Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer (2002) (52)
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies (2013) (52)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice (2016) (51)
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study (2019) (51)
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment (2008) (50)
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? (2009) (50)
AXL is an oncotarget in human colorectal cancer (2015) (50)
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors (2011) (50)
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures (2019) (50)
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. (2001) (49)
Clinical management of advanced gastric cancer: the role of new molecular drugs. (2014) (49)
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. (2016) (49)
EGF-Related Peptides in the Pathophysiology of the Mammary Gland (1997) (49)
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes (2020) (48)
Down‐regulation of riα subunit of camp‐dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c‐ha‐ras and c‐erbb‐2 proto‐oncogenes (1993) (48)
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer (2011) (48)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. (2021) (47)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. (2000) (47)
Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions (2019) (47)
Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. (2014) (47)
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells (2014) (46)
EGF‐related peptides are involved in the proliferation and survival of MDA‐MB‐468 human breast carcinoma cells (1999) (45)
Chemosensitization by antisense oligonucleotides targeting MDM2. (2005) (45)
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. (1997) (45)
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma (2004) (45)
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. (2010) (45)
Clinical management of metastatic colorectal cancer in the era of precision medicine (2022) (45)
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines (2019) (45)
Vascular endothelial growth factor and neo‐angiogenesis in H. pylori gastritis in humans (2005) (44)
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. (2015) (44)
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. (2005) (44)
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases (2006) (44)
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. (2018) (44)
Implication of the Hedgehog pathway in hepatocellular carcinoma (2017) (44)
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. (1997) (44)
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. (2011) (44)
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer (2004) (44)
What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives (2018) (42)
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells (2012) (42)
p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate (2006) (42)
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. (2005) (41)
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. (2018) (41)
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. (2020) (41)
Current status of targeted therapies in advanced gastric cancer (2012) (40)
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. (2004) (40)
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. (2018) (40)
mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. (1989) (40)
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines (2009) (40)
Modulation by estrogen and growth factors of transforming growth factor-alpha and epidermal growth factor receptor expression in normal and malignant human mammary epithelial cells. (1989) (40)
Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model (2007) (40)
A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cance. (2004) (40)
Over‐expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an Estrogen‐independent phenotype (1990) (39)
Anti‐sense oligonucleotides directed against EGF‐related growth factors enhance anti‐proliferative effect of conventional anti‐tumor drugs in human colon‐cancer cells (1997) (39)
Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors (2011) (39)
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). (2020) (38)
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). (2020) (38)
α‐interferon potentiates epidermal growth factor receptor‐mediated effects on human epidermoid carcinoma KB cells (1995) (38)
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (2020) (38)
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study (2018) (38)
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer (2019) (38)
Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. (2000) (37)
Monoclonal antibodies targeting the epidermal growth factor receptor. (2005) (37)
Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). (2006) (37)
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. (2005) (37)
Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models (2011) (36)
Pancreatic neuroendocrine tumors: Nosography, management and treatment. (2016) (36)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. (2016) (36)
Antisense strategies targeting protein kinase C: preclinical and clinical development. (2003) (36)
ALK inhibitors and advanced non-small cell lung cancer (review). (2014) (36)
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (35)
Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells (2008) (35)
A preliminary study for quantitative assessment with HFUS (High Frequency ultrasound) of nodular skin melanoma Breslow thickness in adults before surgery: Interdisciplinary team experience. (2020) (35)
Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A. (1997) (35)
Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. (2014) (34)
It is finally time for adjuvant therapy in melanoma. (2018) (34)
Inhibition of bcl-2 as cancer therapy. (2002) (34)
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. (2006) (34)
KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment (2011) (34)
How we treat metastatic colorectal cancer (2020) (34)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. (2014) (34)
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH tri (2008) (33)
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). (2004) (33)
HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. (2011) (33)
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. (2012) (33)
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. (2011) (33)
Infection with a transforming growth factor α anti‐sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line (1993) (33)
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer (2015) (32)
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. (2018) (32)
Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. (2001) (31)
LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (2015) (31)
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC (2019) (31)
Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. (1998) (30)
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR (2017) (30)
CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. (2004) (30)
3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) (2007) (30)
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells (2018) (29)
Role of the cripto (EGF-CFC) family in embryogenesis and cancer. (2004) (29)
Amphiregulin anti‐sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line (1995) (29)
Differential effects of protein kinase a sub‐units on chinese‐hamster‐ovary cell cycle and proliferation (1994) (29)
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer (2005) (29)
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. (2010) (29)
Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. (1993) (28)
Differential growth factor expression in transformed mouse NIH‐3T3 cells (1990) (28)
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials (2003) (28)
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience (2019) (28)
The role of antiangiogenetic agents in the treatment of breast cancer. (2011) (28)
Response of normal and oncogene‐transformed human mammary epithelial cells to transforming growth factor β1 (TGF‐β1): Lack of growth‐inhibitory effect on cells expressing the simian virus 40 large‐t antigen (1994) (28)
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma (2011) (28)
The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer (2008) (27)
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis (2015) (27)
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. (2007) (27)
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients (2014) (27)
External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. (2003) (27)
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case (2018) (26)
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment (2017) (26)
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. (2007) (26)
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? (2020) (26)
Transformation of mouse mammary epithelial cells with the Ha‐ras but not with the neu oncogene results in a gene dosage‐dependent increase in transforming growth factor‐α production (1989) (26)
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. (2007) (26)
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer (2014) (26)
Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents (2019) (25)
Enhanced expression of heregulin in c‐erb B‐2 and c‐Ha‐ras transformed mouse and human mammary epithelial cells (1996) (25)
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. (1999) (25)
Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives (2018) (25)
HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. (2016) (25)
Metformin in lung cancer: rationale for a combination therapy (2013) (25)
Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study (2006) (25)
Emerging VEGF-receptor inhibitors for colorectal cancer (2013) (25)
PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (2017) (25)
Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times (2019) (25)
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models (2018) (25)
Transfection with a CRIPTO anti‐sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line (1996) (25)
Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy (2003) (25)
Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. (2006) (25)
Combined targeted therapies in non-small cell lung cancer: a winner strategy? (2007) (24)
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells (2008) (24)
Regulation by estrogen through the 5'-flanking region of the transforming growth factor alpha gene. (1991) (24)
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study (2014) (24)
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy (2021) (24)
An update of new targets for cancer treatment: receptor-mediated signals. (2002) (24)
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer (2012) (24)
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies. (2016) (24)
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer (2014) (24)
BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. (2019) (24)
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer (2017) (24)
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations (2020) (23)
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. (2014) (23)
Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer (2008) (23)
Mechanisms of resistance to EGFR inhibitors (2007) (23)
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis (2018) (23)
Medical treatment of small cell lung cancer: state of the art and new development (2013) (23)
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. (2016) (23)
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. (2007) (23)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). (2021) (22)
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression (2019) (22)
Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. (1995) (22)
Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case (2020) (22)
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. (2014) (22)
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2012) (22)
Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. (2010) (22)
Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. (1988) (21)
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. (2021) (21)
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study (2019) (21)
Antiangiogenic drugs in non-small cell lung cancer treatment (2006) (21)
Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). (2019) (21)
Regulation of surface‐differentiation molecules by epidermal growth factor, transforming growth factor alpha, and hydrocortisone in human mammary epithelial cells transformed by an activated c‐Ha‐ras proto‐oncogene (1992) (21)
The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. (1994) (21)
Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline. (1990) (21)
Perspectives in Adjuvant Therapy of Gastric Cancer (2010) (20)
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. (2017) (20)
Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) (2008) (20)
Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases (2019) (20)
Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management (2019) (20)
Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. (2012) (20)
Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer (2017) (20)
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside (2021) (19)
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer (2020) (19)
Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial. (2006) (19)
Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. (2015) (19)
Induction of multidrug resistance (MDR) by transfection of MCF‐10A cell line with c‐Ha‐ras and c‐erbB‐2 oncogenes (1994) (19)
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. (2014) (19)
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment (2002) (19)
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. (2016) (19)
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells (2017) (19)
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. (2007) (18)
Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells. (1994) (18)
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. (2020) (18)
Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study (2010) (18)
Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? (2014) (18)
Expression of transforming growth factor alpha (TGF alpha) in breast cancer. (1991) (18)
Chemoradiotherapy as adjuvant treatment of gastric cancer. (2007) (18)
Resistance mechanisms of tumour cells to EGFR inhibitors (2009) (18)
Protein kinase A type I: a target for cancer therapy. (2002) (18)
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs (2008) (18)
The mouse int-2 gene exhibits basic fibroblast growth factor activity in a basic fibroblast growth factor-responsive cell line. (1990) (18)
Unhealthy diets: a common soil for the association of metabolic syndrome and cancer (2014) (18)
Novel investigational drugs for gastric cancer (2009) (18)
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (2020) (18)
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events (2022) (17)
397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study (2020) (17)
Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial (2019) (17)
Loss of thyrotropin regulation and transforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells. (1993) (17)
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial. (2015) (17)
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. (2006) (16)
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). (2021) (16)
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis (2020) (16)
Constitutive expression of transforming growth factor alpha does not transform rat thyroid epithelial cells. (1991) (16)
Transforming growth factors in human breast cancer. (1989) (16)
3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study (2007) (16)
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models (2019) (16)
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature (2019) (15)
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). (2019) (15)
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. (2005) (15)
Cetuximab in the treatment of colorectal cancer. (2005) (15)
Reduction of RIα Subunit of cAMP‐dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF‐α, c‐Ha‐ras, and c‐erbB‐2 Genes (1993) (15)
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer (2021) (15)
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. (2021) (15)
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. (1999) (15)
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours (2016) (14)
BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. (2018) (14)
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. (2020) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis (2019) (14)
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. (2018) (14)
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients (2020) (14)
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models (2015) (13)
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer. (2013) (13)
The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. (2012) (13)
PD-0024 Phase I/II Study of Folfiri Plus the MEK1/2 Inhibitor Pimasertib (MSC1936369B) as Second-Line Treatment for KRAS Mutated Metastatic Colorectal Cancer (2012) (13)
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme (2017) (13)
O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001) (2020) (13)
Differential growth sensitivity to 4-cis-hydroxy-L-proline of transformed rodent cell lines. (1988) (13)
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. (2019) (13)
Structure-activity relationship, physicochemical and pharmacokinetic properties of AZD2171: A highly potent inhibitor of VEGF receptor tyrosine kinases (2004) (13)
Immunotherapy for head and neck cancer: present and future. (2022) (13)
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (2006) (13)
2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy (2015) (13)
Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer (2016) (13)
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches (2007) (13)
Emerging mitotic inhibitors for non-small cell carcinoma (2013) (12)
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
Emerging drugs targeting PD-1 and PD-L1: reality or hope? (2014) (12)
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (2020) (12)
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. (1998) (12)
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety (2018) (12)
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. (2020) (12)
D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer (2016) (12)
The int-2 gene product acts as a growth factor and substitutes for basic fibroblast growth factor in promoting the differentiation of a normal mouse mammary epithelial cell line. (1992) (12)
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. (2002) (12)
Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. (2013) (12)
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’ (2020) (12)
Endorectal Ultrasound and Magnetic Resonance Imaging for Rectal Cancer Staging: A Modern Multimodality Approach (2021) (12)
Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). (2019) (11)
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). (2018) (11)
Overexpression of the RIα subunit of Protein Kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-Chloro-cyclic Adenosine 3′,5′-Monophosphate in chinese hamster ovary cells. (1994) (11)
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? (2013) (11)
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. (2016) (11)
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. (2003) (11)
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly (2004) (11)
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab (2022) (11)
An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (2011) (11)
Epigenetic mechanisms underlying prostate cancer radioresistance (2021) (10)
Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial. (2016) (10)
LBA-09Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab (2015) (10)
Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial (2018) (10)
Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). (2007) (10)
Disordered metabolism of microfilament proteins, tropomyosin and actin, in mouse mammary epithelial cells expressing the Ha-ras oncogene. (1988) (10)
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. (2018) (10)
International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes (2016) (10)
Lymphomatoid papulosis: overview. (2020) (10)
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) (2017) (10)
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy (2021) (10)
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. (2014) (10)
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer (2021) (10)
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT) (2018) (10)
D02*Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial (2016) (9)
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial (2016) (9)
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. (2021) (9)
Critical appraisal of the use of regorafenib in the management of colorectal cancer (2013) (9)
Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants (2021) (9)
517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC) (2017) (9)
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass (2007) (9)
Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer (2005) (9)
Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial (2008) (9)
Optimizing Anti-EGFR Therapy in Colorectal Cancer (2015) (9)
Growth of cells on a perfluorocarbon-medium interphase: A quantitative assay for anchorage-independent cell growth (2007) (9)
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. (2018) (9)
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives (2022) (9)
The role of ras gene expression and transforming growth factor alpha production in the etiology and progression of rodent and human breast cancer. (1991) (8)
c-Ha-ras transfection and expression of MDR-related genes in MCF-10A human breast cell line. (1997) (8)
Expression of transforming growth factor alpha antisense mRNA inhibits the estrogen-induced production of TGF alpha and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. (1993) (8)
Rationale and Design of MILES-3 and MILES-4 Studies : Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non e Small-Cell Lung Cancer (8)
Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology (2017) (8)
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC) (2010) (8)
Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response (2019) (8)
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts? (2020) (8)
Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells (2019) (8)
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. (2022) (8)
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells. (1996) (8)
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells (2018) (8)
Consensus on the medical treatment of colon cancer (2008) (8)
Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. (2003) (8)
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. (2006) (7)
Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC) (2005) (7)
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? (2016) (7)
Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice (2017) (7)
1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial (2021) (7)
The tyrosine kinase inhibitor ZD 6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells (2010) (7)
36 DETECTION OF KRAS MUTATIONS IN COLORECTAL CARCINOMA PATIENTS WITH AN INTEGRATED PCR/SEQUENCING AND REAL TIME PCR APPROACH (2010) (7)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m) (2016) (7)
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) (2019) (7)
Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies. (2017) (7)
Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial. (2022) (7)
Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population (2020) (7)
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (7)
Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L. (2019) (7)
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? (2018) (7)
Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II trials (2008) (7)
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers (2022) (6)
Maintenance therapy for metastatic colorectal cancer. (2015) (6)
gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study (2016) (6)
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients (2020) (6)
LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors (2021) (6)
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients (2022) (6)
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. (1995) (6)
Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon. (2019) (6)
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study (2021) (6)
Expression of transforming growth factor alpha (TGFa) in breast cancer (1991) (6)
3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules (2007) (6)
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. (2017) (6)
Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016 (2016) (6)
399 POSTER Synergistic antitumor activity of the combination of the multi-targeted tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines (2006) (6)
Treatment of esophagogastric junction carcinoma: an unsolved debate. (2015) (6)
E46Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial) (2015) (5)
O-0020OUTCOME ACCORDING TO TUMOR RAS MUTATION STATUS IN CRYSTAL STUDY PATIENTS WITH METASTATIC COLORECTAL CANCER RANDOMIZED TO FOLFIRI WITH OR WITHOUT CETUXIMAB AS FIRST-LINE TREATMENT (2014) (5)
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells (2017) (5)
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. (2017) (5)
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress. (2018) (5)
Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell’Italia Meridionale (GOIM). (2013) (5)
Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study. (2019) (5)
How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma (2021) (5)
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study (2022) (5)
Preoperative treatment of locally advanced esophageal carcinoma (Review). (2013) (5)
New insights on personalized cancer treatments: a report from the ESMO Congress (2011) (5)
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. (2021) (5)
32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation (2015) (5)
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment (2019) (5)
Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. (2021) (5)
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). (2021) (5)
Immunotherapy in advanced anal cancer: Is the beginning of a new era? (2022) (5)
High-dose recombinant interleukin-2/verapamil combination in advanced cancer. (1996) (5)
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer (2009) (5)
Zd1839 (Iressa™): Preclinical Studies and Pharmacology (2002) (5)
A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). (2009) (5)
Treatment of locally advanced non-small cell lung cancer in the elderly (2005) (5)
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype (2021) (5)
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (5)
Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. (2010) (5)
Light alcohol drinking and the risk of cancer development: a controversial relationship. (2020) (5)
Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer 1 (2002) (5)
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy (2021) (4)
A phase II study of neoadjuvant antiangiogenic therapy combined with capecitabine (C) and radiotherapy (RT) in patients (pts) with locally advanced rectal cancer (LARC) (2008) (4)
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. (2007) (4)
ESMO and WHO: 14 years of working in partnership on cancer control (2016) (4)
LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) (2022) (4)
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits. (1996) (4)
Brexit: a European perspective. (2016) (4)
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway (2022) (4)
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector (2004) (4)
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer (2019) (4)
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment (2006) (4)
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. (2023) (4)
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) (2022) (4)
1379TiPPhase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor (2017) (4)
Prognostic Factors in Human Colorectal Cancer (1997) (4)
MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI (2017) (4)
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant (2019) (4)
757PSafety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis (2017) (4)
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation (2017) (4)
Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). (2012) (4)
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data (2022) (4)
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity (2003) (4)
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience (2022) (4)
Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors (2021) (4)
Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer (2009) (3)
GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype (2019) (3)
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series (2022) (3)
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. (2018) (3)
Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review. (2019) (3)
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer (2007) (3)
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients (2017) (3)
316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study (2022) (3)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials (2021) (3)
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases, blocks VEGF-C-induced activation of VEGFR-3 and cell proliferation in human colon cancer cell lines. (2006) (3)
A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study (2021) (3)
The effect of fgf-3 int-2 on growth and transformation of mcf-10a normal human mammary epithelial-cells is distinct from fgf-1 and fgf-2. (1994) (3)
Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells (2021) (3)
Cooperative inhibition of human renal cancer cell growth by treatment with anti-epidermal growth factor receptor monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I protein kinase A (1998) (3)
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. (2022) (3)
Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. (2017) (3)
Applying the ESMO-Magnitude of Clinical Benefit Scale in real life (2016) (3)
Advances in Brief Helicobacter pylori VacA Toxin UpRegulates Vascular Endothelial Growth Factor Expression in MKN 28 Gastric Cells through an Epidermal Growth Factor Receptor-, Cyclooxygenase-2-dependent Mechanism 1 (2003) (3)
Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report (2020) (3)
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign (2022) (3)
Combination of Standard Chemotherapy and Targeted Agents (2007) (3)
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect (2003) (3)
Effects of mutant p53 genes on transformation of human mammary epithelial-cells. (1994) (3)
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice (2022) (3)
[Rationales for the integration of molecular and conventional therapies]. (2002) (2)
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). (2018) (2)
Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies (2017) (2)
Prognostic implications of baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in metastatic gastric cancer (GC) patients (2016) (2)
Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways (2019) (2)
VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells. (2008) (2)
Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon (2019) (2)
Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report (2008) (2)
Overexpression of the RI alpha subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3'5'-monophosphate in Chinese hamster ovary cells. (1994) (2)
Optimal dose of cetuximab administered every 2 weeks (q2w): A phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) (2007) (2)
The Rationale for the Combination of Selective EGFR Inhibitors with Cytotoxic Drugs and Radiotherapy (2007) (2)
The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer (2013) (2)
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial (2022) (2)
507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer (2020) (2)
Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty (2019) (2)
Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells (2008) (2)
167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials (2021) (2)
PD-012Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC) (2016) (2)
A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC) (2009) (2)
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC (2022) (2)
Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial (2016) (2)
D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL (2016) (2)
SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC (2021) (2)
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR (2022) (2)
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy. (2018) (2)
Mini Review (2004) (2)
Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’ (2012) (2)
397 POSTER Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines (2006) (2)
EPHA2 blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC) (2016) (2)
541PFOLFIRI PLUS CETUXIMAB IN PATIENTS WITH LIVER-LIMITED OR NON-LIVER-LIMITED RAS WILD-TYPE METASTATIC DISEASE: A SUB-GROUP ANALYSIS OF THE CRYSTAL STUDY. (2014) (2)
ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. (2013) (2)
Adjuvant chemotherapy of gastric cancer: which regimens? (2005) (2)
478OEfficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) (2017) (2)
LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC (2020) (2)
Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors: A Phase I Study (2006) (2)
Reply to V. Lorusso et al. (2013) (2)
Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. (2019) (2)
Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combination. (1995) (2)
Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. (2018) (2)
Global BRAF testing practices in metastatic colorectal cancer. (2021) (1)
Clinical Approach: Recommendations for the Clinicians (2018) (1)
Predictive Biomarkers to Anti-EGFR Inhibitors Treatment in the Management of Metastatic Colorectal Cancer (2014) (1)
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC (2017) (1)
The rational basis of using novel targeted biological agents in non-small cell lung cancer. (2002) (1)
TOG 2004 ZD 6474 , AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASE ACTIVITY IN COMBINATION WITH RADIOTHERAPY (2005) (1)
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review (2016) (1)
Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results (2021) (1)
D07Phase II open-label single-arm study of pre-operative panitumumab and external pelvic radiotherapy (RTE) in locally advanced rectal cancer (LARC) patients (pts) (RaP/STAR-03 Study) (2016) (1)
Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer (2023) (1)
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts (2007) (1)
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. (2018) (1)
Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer (2020) (1)
B14The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines (2016) (1)
The search for optimal response prediction in cancer leads to a personalized approach (2010) (1)
Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review (2022) (1)
Trastuzumab Resistance in Breast Cancer (2011) (1)
P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients (2017) (1)
O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials (2022) (1)
P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data (2020) (1)
Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. (2017) (1)
Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy (2019) (1)
Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy (2007) (1)
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. (2010) (1)
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC (2019) (1)
1480OSYMPTOMATIC TOXICITIES EXPERIENCED DURING ANTI-CANCER TREATMENT: COMPARISON OF PATIENTS' AND PHYSICIANS' REPORTING IN THREE RANDOMIZED CONTROLLED TRIALS (RCTS). (2014) (1)
Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic colorectal cancer. (2010) (1)
215PEXPRESSION OF AXL RECEPTOR AND ITS LIGAND GAS6 IN COLORECTAL CANCER (CRC). (2014) (1)
Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. (2018) (1)
The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies. (2018) (1)
Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer (2014) (1)
The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with “Quad WT”. J Clin Oncol 35 (15) 3572. (2013) (1)
Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study. (2018) (1)
Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review (2022) (1)
461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience (2020) (1)
P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) (2017) (1)
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy (2016) (1)
Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus Gemcitabine. (2016) (1)
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 (2022) (1)
Protein Kinases as Targets for Cancer Therapy (2004) (1)
SO-37 Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC (2022) (1)
How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. (2020) (1)
EGFR Inhibitors in Cancer Treatment (2011) (1)
A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine (2021) (1)
MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC. (2019) (1)
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration (2002) (1)
Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant? (2015) (1)
Gestational choriocarcinoma with residual lung tumor after completing treatment: a case report (2021) (1)
E04Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study (2015) (1)
Oral administration of chimeric MBO antisense-protein kinase A inhibits growth, angiogenesis and growth factors production and cooperates with cytotoxic drugs in human cancer xenografts (1999) (1)
Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. (2011) (1)
AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) (2019) (1)
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care (2007) (1)
A factorial phase III randomized trial of rofecoxib and prolonged constant infusion of gemcitabine at 10mg/m2/min (PCI-G) in first-line treatment of adult patients (pts) with advanced non-small cell lung cancer (NSCLC): The GECO study. (2006) (1)
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma (2019) (1)
Global BRAF testing practices in metastatic colorectal cancer (mCRC). (1)
Epidermal growth factor-related growth factors in human colorectal cancer (1995) (1)
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours (2016) (1)
Differential effects of type I and type II protein kinase A isoforms on chinese hamster ovary cell cycle and proliferation. (1994) (1)
O-010KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer (2015) (1)
Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. (2014) (1)
Oncology and public health (2012) (1)
B18GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab (2016) (1)
Overexpression of wild-type p53 overrides the mitogenic effect of ri-alpha subunit of protein-kinase-a in human breast cells. (1995) (1)
Role of the Hedgehog Pathway in Mediating Resistance to Anti-Egfr Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer (2012) (1)
6550 Adjuvant chemoradiation in stage III-IV radically resected gastric cancer patients: a pilot study (2009) (1)
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer. (2021) (1)
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis (2022) (1)
Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. (2018) (1)
PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy. (2021) (1)
Beyond N staging in colorectal cancer: Current approaches and future perspectives (2022) (1)
The role of Coronary Artery Calcification Score in lung cancer patients (2021) (1)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review (2022) (1)
Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusion. (1994) (1)
Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial (2018) (1)
Oncogenes, growth factors, and growth inhibitors in breast cancer (1995) (1)
1080O_PRPHYSICIANS' AWARENESS AND UNDERSTANDING OF PERSONALIZED MEDICINE IN THE TREATMENT OF CANCER AND ITS ADOPTION IN CLINICAL PRACTICE: A MULTINATIONAL SURVEY (2014) (1)
Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors (2014) (1)
Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC). (2013) (1)
AWARENESS AND UNDERSTANDING OF STRATIFIED/PERSONALIZED MEDICINE IN PATIENTS TREATED FOR CANCER: A MULTINATIONAL SURVEY (2012) (1)
Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience. (2019) (1)
103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) (2021) (1)
123PGenotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 (2017) (1)
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial. (2023) (1)
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics (2022) (1)
Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? (2018) (1)
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients (2020) (1)
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer (2022) (1)
Blockade of protein kinase A and BCL-2 by antisense strategy cooperatively inhibits human cancer growth and angiogenesis and induces apoptosis in nude mice (2000) (0)
1223 A model of synergistic antitumour activity of sorafenib, a multikinase inhibitor of Raf, VEGF and PDGF receptors, with anti-EGFR inhibitors (cetuximab and erlotinib) in a panel of colorectal and lung cancer cell lines (2009) (0)
ergistic Antitumor Activity of Sorafenib in Combination Epidermal Growth Factor Receptor Inhibitors in R orectal and Lung Cancer Cells (2010) (0)
Is there a role for maintenance therapy in advanced non-small-cell lung cancer? (2012) (0)
Ipatasertib (GDC-0068), a novel Akt inhibitor, synergizes with anti-microtubule chemotherapic agents in human breast cancer cell lines (2016) (0)
PO-519 Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified colorectal cancer models (2018) (0)
Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models (2016) (0)
HER2 activation and epithelial-mesenchymal transition (EMT) are involved in the acquired resistance to cetuximab in combination with either regorafenib or refametinib (2016) (0)
Type I Isoform of PKA is Involved in the Control of Cell Proliferation and Oncogene Transformation of Human Mammary Epithelial Cells: Therapeutic Implications (1993) (0)
Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells (2019) (0)
428 POSTER Induction of survivin expression via activation of insulin-like growth factor-1 receptor/epidermal growth factor receptor heterodimer: a novel resistance mechanism of EGFR tyrosine kinase inhibitors in non-small cell lung cancer (2006) (0)
A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab. (2018) (0)
New insights from KISS activity: a prognostic biomarker in malignant pleural mesothelioma (2016) (0)
Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis. (2014) (0)
489P Somatic mosaic model of colorectal cancer for translational immune cancer research (2020) (0)
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis (2019) (0)
Delta radiomic parameters for the evaluation of liver metastases in patients with colorectal cancer treated with cetuximab rechallenge plus avelumab in the CAVE mCRC study. (2023) (0)
Oral antisense targeting protein kinase A type I causes antitumor and apoptotic effect in human cancer cells in vitro and in vivo and has cooperative activity in combination with antisense bcl-2. (1999) (0)
539PTUMOR HETEROGENEITY AND EFFICACY OF FIRST-LINE CETUXIMAB + FOLFIRI IN KRAS MUTANT METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) OF THE CAPRI GOIM TRIAL. (2014) (0)
1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL. (2014) (0)
Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part (2008) (0)
Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report (2007) (0)
L38Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem) (2015) (0)
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts (2005) (0)
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma (2023) (0)
Ramucirumab: a new option in advanced gastric cancer (2014) (0)
The role of VEGF receptor signaling in gastrointestinal carcinoma cell migration (2008) (0)
2162 : Synergistic Antitumor Activity of Zd6474, an Inhibitor of VEGFR and EGFR Signaling, With Gemcitabine and Ionizing Radiation Against Pancreatic Cancer (2006) (0)
Reply to S. Debska-Szmich et al. (2015) (0)
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines (2019) (0)
Clinical results with EGFR inhibitors in colorectal cancer (2012) (0)
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer (2023) (0)
Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer (1999) (0)
302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis (2021) (0)
1250PEPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ABCG2 POLYMORPHISMS AND TREATMENT OUTCOME IN THE RANDOMIZED PHASE III TORCH TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. (2014) (0)
36PSynergistic effect of vismodegib and cisplatin in NSCLC models via autophagy (2017) (0)
Diagnosis of malignant pleural disease: Ultrasound as “a detective probe” (2022) (0)
Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models. (2018) (0)
1604PROLE OF HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO EGFR-INHIBITORS IN NON-SMALL CELL LUNG CANCER. (2014) (0)
5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING (2011) (0)
Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study. (2022) (0)
health economicsThe effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials (2016) (0)
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). (2023) (0)
Met Activation by Autocrine Loop Rescues Colon Cancer Cells From Sensitivity to EGFR Inhibition (2012) (0)
The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer (2006) (0)
Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients. (2014) (0)
Basic Science of Lung Cancer in Older Patients (2013) (0)
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC (2023) (0)
Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives (2023) (0)
Intraoperative ventilatory leak: Real-time guidance for management of air leak in lung cancer patients undergoing VATS lobectomy. (2023) (0)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with epidermal growth factor receptor tyrosine kinase inhibitors in human cancer cell lines. (2007) (0)
Vandetanib, a dual inhibitor of VEGFR and EGFR tyrosine kinase activity (2007) (0)
Cetuximab, a chimeric anti-epidermal growth factor receptor monoclonal antibody, in colorectal cancer treatment. (2007) (0)
610TiPA randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients (2017) (0)
Efficacy and feasibility of OncoSmart, a tool for remote detection and monitoring chemoterapy-related adverse events in metastatic colorectal cancer patients: a pilot retrospective study. (Preprint) (2020) (0)
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials (2023) (0)
Abstract 4904: PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in human colorectal cancer models (2018) (0)
Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line. (2018) (0)
The protein kinase C beta antagonist enzastaurin (LY317615.HCl) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells (2006) (0)
1221 Enhanced sensitivity to Bortezomib pro apoptotic effects in human cancer cells with acquired resistance to anti-EGFR TKIs (2009) (0)
Implication of the Insulin-like Growth Factor-IRPathway in the Resistance of Non ^ small Cell Lung Cancer Cells toTreatment with (2007) (0)
D28The FUNNEL: a precision medicine project for metastatic colorectal cancer (2016) (0)
Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells. (2017) (0)
L39Prognostic value of blood neutrophil-to-lymphocyte ratio (NLR)in advanced pancreatic cancer patients treated with Nab-paclitaxel and Gemcitabine: our experience (2015) (0)
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial (2022) (0)
Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine (2016) (0)
407PAntitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells (2017) (0)
Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. (2014) (0)
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network. (2022) (0)
Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of the Second University of Naples (SUN) (2016) (0)
Reply to M.J. Rother (2011) (0)
3O Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer (2020) (0)
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside (2021) (0)
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside (2021) (0)
Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474 (2006) (0)
Ventilation challenge in rigid bronchoscopy: Laser tube as an alternative management in patients with lung cancer and central airway obstruction (2022) (0)
AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC) (2016) (0)
173P Prognostic impact of progesterone receptor levels in luminal-like Her2- early breast cancer patients: A retrospective analysis (2020) (0)
1666PMet/Axl system as a dual target in the mesothelioma pathway and invasiveness (2017) (0)
Abstract CT164: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207 (2023) (0)
Funding: Roche Disclosure: J. Bennouna: Advisory Board for Roche, Boehringer Ingelheim, (2017) (0)
D17Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial (2016) (0)
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells (2003) (0)
2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
New genes involved in the neoplastic transformation of the thyroid gland (2006) (0)
Prognostic significance of progesterone receptor levels in luminal-like Her2- early breast cancer patients. A retrospective single cancer center analysis (2019) (0)
Subject Index Vol. 77, Suppl. 1, 2009 (2010) (0)
Role of pioglitazone on gene/protein expression profile, bioenergetics and TGFβ/SMAD signaling pathway in NSCLC. (2018) (0)
Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model (2019) (0)
Intraoperative ultrasound: “Alternative eye” in lymph nodal dissection in non‐small cell lung cancer (2022) (0)
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research? (2013) (0)
Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC). (2014) (0)
D37Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience (2016) (0)
1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial (2020) (0)
Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). (2023) (0)
Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments (2019) (0)
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer. (2023) (0)
445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor (2021) (0)
P.11.21 SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH A OR B CIRRHOSIS (2013) (0)
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression (2019) (0)
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors. (2022) (0)
32P Prognostic impact of KRAS mutation in cell-free DNA in patients with pancreatic cancer (2017) (0)
Abstract 5712: Identification of a highly suppressive Treg subset associated with immunotherapy response (2018) (0)
EPHA2 receptor is involved in in vivo acquired resistance to anti-epidermal growth factor receptor (EGFR) treatment in metastatic colorectal cancer. (2017) (0)
Adenosine 3′–5′ monophosphate (cAMP) reduces neointima formation and smooth muscle cell proliferation after balloon injury (1998) (0)
24P Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis (2018) (0)
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. (2023) (0)
Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence (2016) (0)
P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution (2020) (0)
EGFR, HER-2/neu, COX-2 and bcl-2 expression in human prostate cancer: Which implications for the treatment of the disease? (2003) (0)
15P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results (2021) (0)
1586PCO-ACTIVATION OF HEDGEHOG AND MET PATHWAYS IN MEDIATING RESISTANCE TO GEFITINIB IN NON-SMALL CELL LUNG CANCER CELL LINE HARBORING ACTIVATING MUTATION OF EGFR. (2014) (0)
Poseban članak Sadašnja i buduća uloga medikalnog onkologa u profesionalnom zbrinjavanju onkoloških pacijenata: stav Evropskog udruženja za medikalnu onkologiju (ESMO) (2014) (0)
P-68 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study (2022) (0)
IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients (2019) (0)
1092P Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) (2022) (0)
P-308RAVELLO trial: Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (2015) (0)
Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial. (2017) (0)
Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR (2022) (0)
Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance (2016) (0)
Cetuximab (2004) (0)
European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. (2023) (0)
Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. (2019) (0)
Towards the era of precision medicine in metastatic colorectal cancer (2020) (0)
ZD1839 (Gefitinib, Iressa): Antitumor activity and potential use in the integrated medical treatment of cancer (2003) (0)
540PAnalysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial (2017) (0)
196P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results (2021) (0)
Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types. (2023) (0)
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. (2023) (0)
Amphiregulin as an autocrine growth factor for cHaras-and c-erbB2-transformed human mammary epithelial cells ( Haras / c-neu / breast cancer ) (0)
1609PROLE OF EGFR AND AXL PATHWAYS IN MEDIATING PROLIFERATION AND INVASIVENESS OF HUMAN MESOTHELIOMA CELL LINES. (2014) (0)
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis (2022) (0)
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts (2005) (0)
Endoscopic treatment of solitary fibrous tumor of the trachea: a case report (2023) (0)
1579POPTIMAL STRATEGY WITH MULTI-TARGETED THERAPIES IN EGFR-DEPENDENT "QUADRUPLE WILD TYPE (WT) FOR KRAS, BRAF, NRAS AND PIK3CA GENES" COLORECTAL CANCER (CRC) XENOGRAFTS AFTER COMBINED TREATMENT OF IRINOTECAN PLUS CETUXIMAB. (2014) (0)
P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy (2021) (0)
Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer (2019) (0)
Abstract 2841: Her2/neu expression as potential marker of regorafenib resistance in CRC (2018) (0)
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma (2022) (0)
643PCELL GROWTH INHIBITION OF HER2 POSITIVE TRASTUZUMAB RESISTANT GASTRIC CANCER CELL LINES BY COMBINED INHIBITION OF PI3K/AKT/MTOR AND MAPK. (2014) (0)
Regional variation in physicians’ awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education. (2015) (0)
D45Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts): a single institution experience (2016) (0)
Epidermal Growth Factor Receptor, but Not c-erbB-2, Activation Prevents Lactogenic Hormone Induction of the 1-Casein Gene in Mouse Mammary Epithelial Cells (0)
1583PPRIMARY AND ACQUIRED RESISTANCE OF COLORECTAL CANCER CELLS TO ANTI-EGFR ANTIBODIES CAN BE OVERCOME BY THE TREATMENT WITH REGORAFENIB IN COMBINATION WITH CETUXIMAB. (2014) (0)
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells (2023) (0)
Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa (2001) (0)
SO-32 Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis (2022) (0)
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells (2018) (0)
Metachronous Gastrointestinal Stromal Tumors (GISTS) or Relapse of the Primary Tumor? A Challenging Case of Multiple GISTS in an Elderly Patient (2020) (0)
Abstract 937: Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity (2014) (0)
PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in a human colorectal cancer model (2016) (0)
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Lowâ•’Risk, Locally Advanced Rectal Cancer (RaP Study/STARâ•’03) (2018) (0)
B23Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines (2016) (0)
183P Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor negative (HER2-) early breast cancer (2020) (0)
Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer (2014) (0)
Light alcohol drinking and the risk of developing cancer, a systematic review. (2019) (0)
Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience (2019) (0)
Optimizing Therapeutic Combinations of a Selective MEK 1/2 Inhibitor (Pimasertib) With PI3K/MTOR Inhibitors or With Multi-Targeted Kinase Inhibitors in Pimasertib-Resistant Human Lung and Colorectal Cancer Cells (2012) (0)
Cetuximab in first line treatment of metastatic colorectal cancer (2012) (0)
Combination Therapy with Anti-EGFR Monoclonal Antibodies in the Treatment of NSCLC (2012) (0)
SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models (2016) (0)
Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer. (2018) (0)
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study (2019) (0)
Cetuximab: A Viewpoint by Fortunato Ciardiello (2004) (0)
Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer. (2020) (0)
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part. (2007) (0)
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 (2004) (0)
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines (2023) (0)
Effects of treatment with sorafenib on the invasive, migratory and anchorage-independent colony forming capabilities of TKI-resistant CALU-3 and HCT116 cancer cells. (2013) (0)
Geftinib: A Viewpoint by Fortunato Ciardiello (2002) (0)
[EGF receptor blockade with monoclonal antibodis and so-called "small molecules"]. (2005) (0)
Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G). (2014) (0)
Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment (2019) (0)
507TiP PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer (2021) (0)
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. (1996) (0)
D31Outcomes of elderly chemorefractory metastatic colorectal (mCRC) patients (pts) treated with regorafenib: a single institution experience (2016) (0)
The Cancer Moonshot from a European perspective. (2017) (0)
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models (2019) (0)
Enabling smart environment for monitoring cancer patients therapy through OncoSmart (2022) (0)
Symptoms Adversely Impact Survival Among Patients With Cancer and Unsuspected Pulmonary Embolism (2011) (0)
Intrinsic Resistance To the Antiproliferative Effects of Azd6244 a Selective Mek1/2 Inhibitor Is Associated With Concomitant K-ras and Pi3kca Gene Mutations in Colorectal Cancer Cells (2010) (0)
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations (2016) (0)
660PINCREASED VEGF-C SERUM LEVELS ARE PREDICTIVE OF A POOR OUTCOME IN PATIENTS WITH RESECTABLE GASTRIC CANCER. (2014) (0)
P-284Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup (2015) (0)
Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy. (2015) (0)
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. (2023) (0)
6565 The role of PET-TC in predicting the pCR in locally-advanced esophageal cancer (LAEC) after a preoperative CT-RT treatment: data from B152 trial (2009) (0)
The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling. (2017) (0)
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures (2019) (0)
Identification of a highly suppressive Treg subset associated to immunotherapy response. (2018) (0)
Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors (2007) (0)
84MO A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 (2020) (0)
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance toAnti ^ Epidermal Growth Factor Receptor Drugs in Human Cancer Cells (2008) (0)
Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience. (2014) (0)
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic (2022) (0)
EPHA2 Is aPredictiveBiomarkerofResistanceand a Potential Therapeutic Target for Improving AntiepidermalGrowthFactorReceptor Therapy in Colorectal Cancer (2019) (0)
BRIEF REPORTS Flow-Cytometric Detection of the RIa Subunit of Type I CAMP-Dependent Protein Kinase in Human Cells (2004) (0)
Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites: 51PD (2018) (0)
The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes (2015) (0)
Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status (2019) (0)
Author Reply (0)
and can be overcome by combined MEK / EGFR inhibition activationanti-EGFR antibodies converge on MEK / ERK pathway Primary and acquired resistance of colorectal cancer cells (2014) (0)
The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine. (2015) (0)
Abstract PO-052: A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort (2021) (0)
Taselisib enhances effects of anti-microtubule chemotherapic agents in phosphatidylinositol 3-kinase (PI3Ka) mutant breast cancer cell lines (2016) (0)
Doctorate Program in Molecular Oncology and Endocrinology XVIII cycle-2002–2006 Coordinator: Prof. Giancarlo Vecchio “NOVEL MECHANISMS RESPONSIBLE FOR CONTROLLING GLUCOSE-INDUCED INSULIN SECRETION IN PANCREATIC BETA-CELLS” (2006) (0)
1636PEPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC) (2017) (0)
Role and targeting of anaplastic lymphoma kinase in cancer (2018) (0)
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study (2023) (0)
1585PAXL TYROSINE KINASE RECEPTOR AS A KEY REGULATOR OF PROLIFERATION AND SURVIVAL IN COLORECTAL CANCER (CRC). (2014) (0)
Postoperative chemoradiation FOLFOX 4-based for R1 resected gastric cancer: A retrospective mono-institutional study. (2014) (0)
280 Use of biologics in drug development (2009) (0)
5PDThe acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling (2017) (0)
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice (2016) (0)
2392 Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy (2015) (0)
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial (2023) (0)
Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer (2008) (0)
28 Synergistic antiproliferative effects of ionizing radiations with anti-epidermal growth factor receptor monoclonal antibody C225 and protein kinase a antisense oligonucleotide hyb 165 (1999) (0)
Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis on the efficacy and safety profile. (2017) (0)
FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma (2023) (0)
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer (2003) (0)
A30Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial (2016) (0)
436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment (2022) (0)
A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC (2019) (0)
Epigenetic mechanisms underlying prostate cancer radioresistance (2021) (0)
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway (2022) (0)
SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC (2020) (0)
Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors (2016) (0)
Doctorate Program in Molecular Oncology and Endocrinology (2006) (0)
Transforming growth factor beta receptor (TGFβR) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines (2016) (0)
P-062Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy (2015) (0)
Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data. (2019) (0)
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. (2017) (0)
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC (2022) (0)
79. Over expression of protein kinase subunits differentially affects morphology, growth and differentiation of human and rodent epithelial cells (1992) (0)
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. (2004) (0)
Functional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor. (2018) (0)
1951P Niraparib and irinotecan combination in ATM-mutated colorectal cancer (2020) (0)
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). (2022) (0)
The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions. (2023) (0)
6th Educational Meeting “Colorectal Cancer” (2016) (0)
1199PEffect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites (2017) (0)
16PPhosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells (2017) (0)
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fortunato Ciardiello?

Fortunato Ciardiello is affiliated with the following schools: